New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
09:28 EDTREGNRegeneron reports 85.5% of patients achieve EASI-50 in study of dupilumab
Regeneron disclosed in a regulatory filing that on March 4, at the annual meeting of the American Academy of Allergy, Asthma & Immunology, data from a Phase 2a trial evaluating dupilumab, a human monoclonal antibody, in patients with atopic dermatitis were presented at an oral session by Prof. Diamant Thaci. The data presented in slides show 85.5% of patients showed a reduction of EASI-50 over 12 weeks and EASI-75 reduction was seen in 61.8% of patients over 12 weeks.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
08:36 EDTREGNPiper Jaffray conference call is cancelled
Biopharmaceuticals Analyst Schimmer, along with Dr. Diana Do, a leading clinician-scientist who specializes in the treatment of retinal conditions at the University of Nebraska, discuss the current practice dynamics and treatment of wet-AMD (age-related macular degeneration), the recent AAVL Phase 2a dataset and key points of debate and emerging treatment options in wet-AMD on an Analyst/Industry conference call to be held on July 7 at 4:30 pm.
June 26, 2015
05:25 EDTREGNRegeneron reports approval of Eylea by Japan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use